Immunogenicity and Safety of an Investigational Fully Liquid Hexavalent Combination Vaccine Versus Licensed Combination Vaccines at 6, 10, and 14 Weeks of Age in Healthy South African Infants
Authors:
- Ismail MithaIMIsmail Mitha
- Clare CutlandCCClare Cutland
- Michelle GroomeMGMichelle Groome
- Eduardo Santos-LimaESEduardo Santos-Lima
- 1 April 2011
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 30 (4) , e68-e74
Abstract
Assessment of primary vaccination of a new fully liquid, hexavalent investigational DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) in South African infants. Infants were randomized to the following at 6, 10, and 14 weeks of age (Expanded Program on Immunization schedule): DTaP-IPV-Hep B-PRP-T (Group 1; N = 286); DTwP-Hib, hepatitis B, and OPV vaccines (Group 2; N = 286); or DTaP-IPV-Hep B-PRP-T vaccine with hepatitis B vaccine at birth (Group 3; N = 143). Antibody titers were measured before vaccination (pertussis toxoid, filamentous hemagglutinin) and postprimary vaccination (all valences). Noninferiority analyses were performed for Group 1 versus Group 2 for seroprotection rates. Safety was evaluated from parental reports. Noninferiority (Group 1 minus Group 2) was demonstrated for anti-HBs, -PRP, -diphtheria, -tetanus, and -polio 1, 2, 3 (lower 95% confidence interval for the difference was -8.20 to 3.46). Anti-HBs antibody titers ≥10 mIU/mL and anti-PRP ≥0.15 μg/mL were ≥95.4% in each group. Seroprotection rates were also high for the other antigens. Seroconversion rates (4-fold increase from pre- to postvaccination) were 93.6%, 83.2%, and 95.1% in Groups 1, 2, and 3, respectively, for anti-pertussis toxoid and 93.1%, 57.7%, and 90.0% for anti-filamentous hemagglutinin. Anti-HBs GMTs were 330, 148, and 1913 mIU/mL for Groups 1, 2, and 3, respectively. Reactogenicity was similar in each group. Fever ≥39.0°C occurred in 1.7%, 0.4%, and 0.0% of infants in Groups 1, 2, and 3, respectively; no extensive limb swelling, hypotonic-hyporesponsive episodes, or vaccine-related serious adverse events were reported. The new, fully liquid, investigational hexavalent vaccine in the Expanded Program on Immunization schedule, with/without hepatitis B at birth, is highly immunogenic and safe compared with control vaccines, warranting further development.Keywords
This publication has 11 references indexed in Scilit:
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010
- Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 yearsVaccine, 2010
- Review of 8 years of experience with Infanrix hexa™ (DTPa–HBV–IPV/Hib hexavalent vaccine)Expert Review of Vaccines, 2009
- Immunogenicity of a two-component (PT&FHA) acellular pertussis vaccine in various combinationsHuman Vaccines, 2008
- DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa???)Drugs, 2003
- Immunologic correlates of protection induced by vaccinationThe Pediatric Infectious Disease Journal, 2001
- Interval estimation for the difference between independent proportions: comparison of eleven methodsStatistics in Medicine, 1998
- Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicityVaccine, 1997
- Combination vaccinesThe Pediatric Infectious Disease Journal, 1994
- Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non‐zero risk difference or non‐unity relative riskStatistics in Medicine, 1990